Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill & Intangibles (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Goodwill & Intangibles for 8 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles changed 0.07% to $59.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.0 million through Dec 2025, changed 0.07% year-over-year, with the annual reading at $59.0 million for FY2025, 0.07% changed from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $59.0 million at Akebia Therapeutics, roughly flat from $59.0 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $190.2 million in Q1 2021, with the low at $59.0 million in Q4 2024.
  • Average Goodwill & Intangibles over 5 years is $112.5 million, with a median of $108.6 million recorded in 2023.
  • The sharpest move saw Goodwill & Intangibles crashed 43.58% in 2021, then rose 0.07% in 2025.
  • Over 5 years, Goodwill & Intangibles stood at $167.1 million in 2021, then fell by 21.57% to $131.1 million in 2022, then dropped by 27.46% to $95.1 million in 2023, then plummeted by 37.95% to $59.0 million in 2024, then increased by 0.07% to $59.0 million in 2025.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $59.0 million, $59.0 million, and $59.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.